Civic Intelligence

Chiari & Syringomyelia Research Foundation Inc

EIN 20-1959386 • 501(c)3 • West Seneca, NY

Profile

Searching for better understanding, treatments and cures for chiari malformation (cm), syringomyelia (sm), neuropathic pain and related disorders.

228 Garry DriveWest Seneca, NY 14224

www.columnofhope.org

Siviq Scores

Precomputed percentiles relative to similar nonprofits. These scores are descriptive rather than judgmental.

Liabilities / Assets

Score unavailable

No value available

Liabilities-to-assets requires both liabilities and assets on the latest valid filing.

Source year 2024

Liabilities / Revenue

Score unavailable

No value available

Liabilities-to-revenue requires both liabilities and revenue on the latest valid filing.

Source year 2024

Net Margin

93rd percentile

91%

Higher net margin than 93% of similar nonprofits.

NTEE H • <$500k nonprofits • Source year 2024

Top Officer Pay

92nd percentile

$0

Higher top officer pay than 92% of similar nonprofits.

Top officer pay equals 0.0% of source-year revenue.

NTEE H • <$500k nonprofits • Source year 2024

Asset Growth

59th percentile

4.7%

Faster asset growth than 59% of similar nonprofits.

NTEE H • <$500k nonprofits • Annualized from 2023 to 2024

Revenue Growth

66th percentile

20%

Faster revenue growth than 66% of similar nonprofits.

NTEE H • <$500k nonprofits • Annualized from 2023 to 2024

Assets

Up

$305,254

Up $13,643 (+4.7%) from 2023

Liabilities

-

No earlier filing loaded for comparison.

Net Assets

$305,254

No earlier filing loaded for comparison.

Revenue

Up

$14,943

Up $2,441 (+20%) from 2023

Expenses

Down

$1,300

Down $56,467 (-98%) from 2023

Net Income

Up

$13,643

Up $58,908 (+130%) from 2023

Trend Graphs

Balance Sheet Trend

Grouped bars show assets, liabilities, and net assets across loaded filings.

$400K$300K$200K$100K$0Assets 2010: $172,256Liabilities 2010: $12,321Net Assets 2010: $159,9352010Assets 2011: $194,055Liabilities 2011: $3,017Net Assets 2011: $191,0382011Assets 2012: $237,336Liabilities 2012: $45,936Net Assets 2012: $191,4002012Assets 2013: $197,027Liabilities 2013: $0Net Assets 2013: $197,0272013Assets 2014: $243,596Liabilities 2014: $3,483Net Assets 2014: $240,1132014Assets 2015: $235,113Liabilities 2015: $7,207Net Assets 2015: $227,9062015Assets 2016: $244,493Liabilities 2016: $12,929Net Assets 2016: $231,5642016Assets 2017: $194,068Liabilities 2017: $1,377Net Assets 2017: $192,6912017Assets 2018: $201,658Liabilities 2018: $1,032Net Assets 2018: $200,6262018Assets 2019: $280,537Liabilities 2019: $733Net Assets 2019: $279,8042019Assets 2020: $331,152Liabilities 2020: $1,251Net Assets 2020: $329,9012020Assets 2021: $321,935Net Assets 2021: $321,9352021Assets 2022: $336,876Net Assets 2022: $336,8762022Assets 2023: $291,611Liabilities 2023: $02023Assets 2024: $305,254Net Assets 2024: $305,2542024

Highlighted filing

2024

Assets$305,254
Liabilities-
Net Assets$305,254

Operations Trend

Revenue, expenses, and net income by year, with the latest filing highlighted.

$200K$100K$0-$100KRevenue 2010: $98,599Expenses 2010: $57,213Net Income 2010: $41,3862010Revenue 2011: $69,145Expenses 2011: $38,042Net Income 2011: $31,1032011Revenue 2012: $73,943Expenses 2012: $73,581Net Income 2012: $3622012Revenue 2013: $63,722Expenses 2013: $58,095Net Income 2013: $5,6272013Revenue 2014: $57,523Expenses 2014: $14,437Net Income 2014: $43,0862014Revenue 2015: $68,230Expenses 2015: $80,304Net Income 2015: -$12,0742015Revenue 2016: $77,140Expenses 2016: $73,706Net Income 2016: $3,4342016Revenue 2017: $67,841Expenses 2017: $106,713Net Income 2017: -$38,8722017Revenue 2018: $89,135Expenses 2018: $81,200Net Income 2018: $7,9352018Revenue 2019: $157,863Expenses 2019: $78,685Net Income 2019: $79,1782019Revenue 2020: $51,531Expenses 2020: $1,435Net Income 2020: $50,0962020Revenue 2021: $47,651Expenses 2021: $55,617Net Income 2021: -$7,9662021Revenue 2022: $19,027Expenses 2022: $4,086Net Income 2022: $14,9412022Revenue 2023: $12,502Expenses 2023: $57,767Net Income 2023: -$45,2652023Revenue 2024: $14,943Expenses 2024: $1,300Net Income 2024: $13,6432024

Highlighted filing

2024

Revenue$14,943
Expenses$1,300
Net Income$13,643

Filings

Balance SheetOperations
YearAssetsLiabilitiesNet AssetsRevenueExpensesNet Income
2024Detailed filing. Detailed filing data is available for this year.$3.05$3.05$0.15$0.01$0.14
2023Summary only. Only limited summary data is available for this year.$2.92$0.00$0.13$0.58$0.45
2022XML pending. An XML filing is linked for this year, but detailed extraction is still pending.$3.37$3.37$0.19$0.04$0.15
2021XML pending. An XML filing is linked for this year, but detailed extraction is still pending.$3.22$3.22$0.48$0.56$0.08
2020Detailed filing. Detailed filing data is available for this year.$3.31$0.01$3.30$0.52$0.01$0.50
2019XML pending. An XML filing is linked for this year, but detailed extraction is still pending.$2.81$0.01$2.80$1.58$0.79$0.79
2018XML pending. An XML filing is linked for this year, but detailed extraction is still pending.$2.02$0.01$2.01$0.89$0.81$0.08
2017XML pending. An XML filing is linked for this year, but detailed extraction is still pending.$1.94$0.01$1.93$0.68$1.07$0.39
2016XML pending. An XML filing is linked for this year, but detailed extraction is still pending.$2.44$0.13$2.32$0.77$0.74$0.03
2015Detailed filing. Detailed filing data is available for this year.$2.35$0.07$2.28$0.68$0.80$0.12
2014Detailed filing. Detailed filing data is available for this year.$2.44$0.03$2.40$0.58$0.14$0.43
2013XML pending. An XML filing is linked for this year, but detailed extraction is still pending.$1.97$0.00$1.97$0.64$0.58$0.06
2012Facts available. Structured filing facts are available, but richer extracted sections are limited.$2.37$0.46$1.91$0.74$0.74$0.00
2011Facts available. Structured filing facts are available, but richer extracted sections are limited.$1.94$0.03$1.91$0.69$0.38$0.31
2010Facts available. Structured filing facts are available, but richer extracted sections are limited.$1.72$0.12$1.60$0.99$0.57$0.41
Latest Filing Detail
Jump To
Filing Snapshot
Filing Period
Jan 1, 2024 to Dec 31, 2024
Signed
May 11, 2025
Return Version
2024v5.0
Gross Receipts
$14,943
Mission and Program Overview

Mission

Searching for better understanding, treatments and cures for chiari malformation (cm), syringomyelia (sm), neuropathic pain and related disorders

Program Services

DescriptionGrantsExpenses
INVESTIGATION OF THE DEVELOPMENT AND POSSIBLE TREATMENT OF CHIARI MALFORMATION. ONGOING STUDIES: PATHOPHYSIOLOGY AND TREATMENT OF CHIARI MALFORMATION AND SYRINGOMYELIA - AUSTRALIA COSPONSORED STUDY "IDENTIFYING CHANGES IN COGNITION AND PAIN NETWORKS IN CHIARI PATIENTS (USING FMRI)" - WISCONSIN, US. THE STUDY IS IN THE DATA ANALYSIS STAGE WITH HOPES OF PUBLICATION IN 2025. SUPPORTING LARGER GOVERNMENT SPONSORED STUDY BY SPONSORING EXPERTS NOT FULLY FUNDED BY THE STUDY. CHIARI MALFORMATION: DEFINING PATHOPHYSIOLOGY & TREATMENT GOALS--
UNDERSTANDING THE BIOLOGY, CHEMISTRY, AND FLUID DYNAMICS OF POST TRAUMATIC SYRINGOMYELIA TO UNDERSTAND ALL FORMS OF SYRINGOMYELIA. RECENT PUBLICATIONS: "INVESTIGATING POST-TRAUMATIC SYRINGOMYELIA AND LOCAL FLUID OSMOREGULATION VIA A RAT MODEL" FLUIDS & BARRIERS OF THE CNS - FEBRUARY 2024 CURRENT PLANS INCLUDE: A)EXECUTING ON OUR PLAN TO COMPARE RECENT POSITIVE SURGICAL RESULTS TREATING CHIARI HEADACHE, COGNITIVE IMPACTS, AND RESOLUTION OF SYRINGOMYELIA TO CONTRAST WITH PATIENTS WITH LESS SUCCESSFUL SURGERIES. A.THIS INCLUDES A COMMITMENT OF US90,852 TO ANALYZE DATA FROM A SIGNIFICANT DATA SET OF PATIENTS IN AUSTRALIA AND CHINA. B.COLUMN OF HOPE AND THE PRIMARY INVESTIGATOR WILL WORK TO EXPAND THE DATA SET TO INCLUDE PATIENTS OF MORE THOUGHT LEADERS IN THE FIELD. B)DETERMINING THE NEXT STEPS IN RESOLVING SYRINGOMYELIA, USING THE POST TRAUMATIC SYRINGOMYELIA MODELS AND THE CHARI SURGERY STUDY RESULTS.--
Compensation and Service Providers

Employees

NameTitleFull / Part TimeBaseOtherTotal
MARK S KANEPresidentPT$0--
BARBARA KANESecretary-$0--
KEVIN STRINGERVice Preside-$0--
JEFF MILLERTreasurer-$0--
LAURA HOLENADirector-$0--
Filing and Contact Details

Filer

Filer Name
Chiari & Syringomyelia Research
EIN
20-1959386
Phone
7166337022
Address
228 GARRY DRIVE, WEST SENECA, NY 14224

Signing Officer

Name
Mark S Kane
Title
President
Phone
7166337022
Signed
2025-05-11
Discuss with paid preparer
Yes

Preparer

Firm
Edward L Arcara CPA Pc
Address
465 FRANKLIN ST, BUFFALO, NY 14202-1301
Preparer
Edward L Arcara CPA
Phone
7168842492
Supplemental Narrative

Additional Explanations

Form 990-ez, Part I

Form 990-ez, part i, line 8 medical research conference revenue

Form 990-ez, Part I, Line 16

Expenses bank fees 103 other administrative exp 100 fundraising expenses 1,097 total 1,300

Form 990-ez, Part III

Searching for better understanding, treatments and cures for chiari malformation (cm), syringomyelia (sm), neuropathic pain and related disorders

Form 990-ez, Part III, Line 28

Investigation of the development and possible treatment of chiari malformation. Ongoing studies: pathophysiology and treatment of chiari malformation and syringomyelia - australia cosponsored study "identifying changes in cognition and pain networks in chiari patients (using fmri)" - wisconsin, us. The study is in the data analysis stage with hopes of publication in 2025. Supporting larger government sponsored study by sponsoring experts not fully funded by the study. Chiari malformation: defining pathophysiology & treatment goals

Form 990-ez, Part III, Line 29

Understanding the biology, chemistry, and fluid dynamics of post traumatic syringomyelia to understand all forms of syringomyelia. Recent publications: "investigating post-traumatic syringomyelia and local fluid osmoregulation via a rat model" fluids & barriers of the cns - february 2024 current plans include: a)executing on our plan to compare recent positive surgical results treating chiari headache, cognitive impacts, and resolution of syringomyelia to contrast with patients with less successful surgeries. A.this includes a commitment of us90,852 to analyze data from a significant data set of patients in australia and china. B.column of hope and the primary investigator will work to expand the data set to include patients of more thought leaders in the field. B)determining the next steps in resolving syringomyelia, using the post traumatic syringomyelia models and the chari surgery study results.

Raw XML Appendix139 raw XML fields

This appendix keeps the raw XML leaves available for debugging and edge-case review. The human report above is the primary experience.

Path#Value
IRS990EZ/ActivitiesNotPreviouslyRptInd0false
IRS990EZ/BooksInCareOfDetail/PersonNm0MARK S KANE
IRS990EZ/BooksInCareOfDetail/PhoneNum07166337022
IRS990EZ/BooksInCareOfDetail/USAddress/AddressLine1Txt0228 GARRY DRIVE
IRS990EZ/BooksInCareOfDetail/USAddress/CityNm0WEST SENECA
IRS990EZ/BooksInCareOfDetail/USAddress/StateAbbreviationCd0NY
IRS990EZ/BooksInCareOfDetail/USAddress/ZIPCd014224
IRS990EZ/CashSavingsAndInvestmentsGrp/BOYAmt0291611
IRS990EZ/CashSavingsAndInvestmentsGrp/EOYAmt0305254
IRS990EZ/ChgMadeToOrgnzngDocNotRptInd0false
IRS990EZ/ContributionsGiftsGrantsEtcAmt05508
IRS990EZ/DonorAdvisedFndsInd0false
IRS990EZ/EngagedInExcessBenefitTransInd0false
IRS990EZ/ExcessOrDeficitForYearAmt013643
IRS990EZ/FiledScheduleAInd0true
IRS990EZ/ForeignFinancialAccountInd0false
IRS990EZ/ForeignOfficeInd0false
IRS990EZ/Form1120PolFiledInd0false
IRS990EZ/Form990TotalAssetsGrp/BOYAmt0291611
IRS990EZ/Form990TotalAssetsGrp/EOYAmt0305254
IRS990EZ/GrossReceiptsAmt014943
IRS990EZ/InfoInScheduleOPartIIIInd0X
IRS990EZ/InfoInScheduleOPartIInd0X
IRS990EZ/InvestmentIncomeAmt09435
IRS990EZ/LobbyingActivitiesInd0false
IRS990EZ/MadeLoansToFromOfficersInd0false
IRS990EZ/MethodOfAccountingAccrualInd0X
IRS990EZ/NetAssetsOrFundBalancesBOYAmt0291611
IRS990EZ/NetAssetsOrFundBalancesEOYAmt0305254
IRS990EZ/NetAssetsOrFundBalancesGrp/BOYAmt0291611
IRS990EZ/NetAssetsOrFundBalancesGrp/EOYAmt0305254
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt05.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt12.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt21.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt31.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt41.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt10
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt20
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt30
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt40
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm0MARK S KANE
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm1BARBARA KANE
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm2KEVIN STRINGER
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm3JEFF MILLER
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm4LAURA HOLENA
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt0PRESIDENT
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt1SECRETARY
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt2VICE PRESIDE
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt3TREASURER
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt4DIRECTOR
IRS990EZ/OperateHospitalInd0false
IRS990EZ/Organization501c3Ind0X
IRS990EZ/OrganizationDissolvedEtcInd0false
IRS990EZ/OrganizationHadUBIInd0false
IRS990EZ/OtherExpensesTotalAmt01300
IRS990EZ/PartVIHghstPdCntrctProfSrvcTxt0NONE
IRS990EZ/PartVIOfCompOfHghstPdEmplTxt0NONE
IRS990EZ/PoliticalCampaignActyInd0false
IRS990EZ/PrimaryExemptPurposeTxt0SEARCHING FOR BETTER UNDERSTANDING, TREATMENTS AND CURES FOR CHIARI MALFORMATION (CM), SYRINGOMYELIA (SM), NEUROPATHIC PAIN AND RELATED DISORDERS
IRS990EZ/ProgramSrvcAccomplishmentGrp/DescriptionProgramSrvcAccomTxt0INVESTIGATION OF THE DEVELOPMENT AND POSSIBLE TREATMENT OF CHIARI MALFORMATION. ONGOING STUDIES: PATHOPHYSIOLOGY AND TREATMENT OF CHIARI MALFORMATION AND SYRINGOMYELIA - AUSTRALIA COSPONSORED STUDY "IDENTIFYING CHANGES IN COGNITION AND PAIN NETWORKS IN CHIARI PATIENTS (USING FMRI)" - WISCONSIN, US. THE STUDY IS IN THE DATA ANALYSIS STAGE WITH HOPES OF PUBLICATION IN 2025. SUPPORTING LARGER GOVERNMENT SPONSORED STUDY BY SPONSORING EXPERTS NOT FULLY FUNDED BY THE STUDY. CHIARI MALFORMATION: DEFINING PATHOPHYSIOLOGY & TREATMENT GOALS
IRS990EZ/ProgramSrvcAccomplishmentGrp/DescriptionProgramSrvcAccomTxt1UNDERSTANDING THE BIOLOGY, CHEMISTRY, AND FLUID DYNAMICS OF POST TRAUMATIC SYRINGOMYELIA TO UNDERSTAND ALL FORMS OF SYRINGOMYELIA. RECENT PUBLICATIONS: "INVESTIGATING POST-TRAUMATIC SYRINGOMYELIA AND LOCAL FLUID OSMOREGULATION VIA A RAT MODEL" FLUIDS & BARRIERS OF THE CNS - FEBRUARY 2024 CURRENT PLANS INCLUDE: A)EXECUTING ON OUR PLAN TO COMPARE RECENT POSITIVE SURGICAL RESULTS TREATING CHIARI HEADACHE, COGNITIVE IMPACTS, AND RESOLUTION OF SYRINGOMYELIA TO CONTRAST WITH PATIENTS WITH LESS SUCCESSFUL SURGERIES. A.THIS INCLUDES A COMMITMENT OF US90,852 TO ANALYZE DATA FROM A SIGNIFICANT DATA SET OF PATIENTS IN AUSTRALIA AND CHINA. B.COLUMN OF HOPE AND THE PRIMARY INVESTIGATOR WILL WORK TO EXPAND THE DATA SET TO INCLUDE PATIENTS OF MORE THOUGHT LEADERS IN THE FIELD. B)DETERMINING THE NEXT STEPS IN RESOLVING SYRINGOMYELIA, USING THE POST TRAUMATIC SYRINGOMYELIA MODELS AND THE CHARI SURGERY STUDY RESULTS.
IRS990EZ/ProgramSrvcAccomplishmentGrp/ForeignGrantsInd0X
IRS990EZ/ProhibitedTaxShelterTransInd0false
IRS990EZ/RelatedOrganizationCtrlEntInd0false
IRS990EZ/ScheduleBNotRequiredInd0X
IRS990EZ/SchoolOperatingInd0false
IRS990EZ/StatesWhereCopyOfReturnIsFldCd0NY
IRS990EZ/SubjectToProxyTaxInd0false
IRS990EZ/TanningServicesProvidedInd0false
IRS990EZ/TotalExpensesAmt01300
IRS990EZ/TotalRevenueAmt014943
IRS990EZ/TransactionWithControlEntInd0false
IRS990EZ/TrnsfrExmptNonChrtblRltdOrgInd0false
IRS990EZ/TypeOfOrganizationCorpInd0X
IRS990EZ/WebsiteAddressTxt0WWW.COLUMNOFHOPE.ORG
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearAmt05508
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus1YearAmt011776
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus2YearsAmt018819
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus3YearsAmt047641
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus4YearsAmt051454
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/TotalAmt0135198
IRS990ScheduleA/GrossInvestmentIncome170Grp/CurrentTaxYearAmt09435
IRS990ScheduleA/GrossInvestmentIncome170Grp/CurrentTaxYearMinus4YearsAmt077
IRS990ScheduleA/GrossInvestmentIncome170Grp/TotalAmt09512
IRS990ScheduleA/GrossReceiptsRltdActivitiesAmt01021
IRS990ScheduleA/PublicOrganization170Ind0X
IRS990ScheduleA/PublicSupportCY170Pct00.73990
IRS990ScheduleA/PublicSupportPY170Pct00.61120
IRS990ScheduleA/PublicSupportTotal170Amt0107076
IRS990ScheduleA/SubstantialContributorsTotAmt028122
IRS990ScheduleA/ThirtyThrPctSuprtTestsCY170Ind0X
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearAmt05508
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus1YearAmt011776
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus2YearsAmt018819
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus3YearsAmt047641
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus4YearsAmt051454
IRS990ScheduleA/TotalCalendarYear170Grp/TotalAmt0135198
IRS990ScheduleA/TotalSupportAmt0144710
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt0FORM 990-EZ, PART I, LINE 8 MEDICAL RESEARCH CONFERENCE REVENUE
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt1EXPENSES BANK FEES 103 OTHER ADMINISTRATIVE EXP 100 FUNDRAISING EXPENSES 1,097 TOTAL 1,300
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt2SEARCHING FOR BETTER UNDERSTANDING, TREATMENTS AND CURES FOR CHIARI MALFORMATION (CM), SYRINGOMYELIA (SM), NEUROPATHIC PAIN AND RELATED DISORDERS
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt3INVESTIGATION OF THE DEVELOPMENT AND POSSIBLE TREATMENT OF CHIARI MALFORMATION. ONGOING STUDIES: PATHOPHYSIOLOGY AND TREATMENT OF CHIARI MALFORMATION AND SYRINGOMYELIA - AUSTRALIA COSPONSORED STUDY "IDENTIFYING CHANGES IN COGNITION AND PAIN NETWORKS IN CHIARI PATIENTS (USING FMRI)" - WISCONSIN, US. THE STUDY IS IN THE DATA ANALYSIS STAGE WITH HOPES OF PUBLICATION IN 2025. SUPPORTING LARGER GOVERNMENT SPONSORED STUDY BY SPONSORING EXPERTS NOT FULLY FUNDED BY THE STUDY. CHIARI MALFORMATION: DEFINING PATHOPHYSIOLOGY & TREATMENT GOALS
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt4UNDERSTANDING THE BIOLOGY, CHEMISTRY, AND FLUID DYNAMICS OF POST TRAUMATIC SYRINGOMYELIA TO UNDERSTAND ALL FORMS OF SYRINGOMYELIA. RECENT PUBLICATIONS: "INVESTIGATING POST-TRAUMATIC SYRINGOMYELIA AND LOCAL FLUID OSMOREGULATION VIA A RAT MODEL" FLUIDS & BARRIERS OF THE CNS - FEBRUARY 2024 CURRENT PLANS INCLUDE: A)EXECUTING ON OUR PLAN TO COMPARE RECENT POSITIVE SURGICAL RESULTS TREATING CHIARI HEADACHE, COGNITIVE IMPACTS, AND RESOLUTION OF SYRINGOMYELIA TO CONTRAST WITH PATIENTS WITH LESS SUCCESSFUL SURGERIES. A.THIS INCLUDES A COMMITMENT OF US90,852 TO ANALYZE DATA FROM A SIGNIFICANT DATA SET OF PATIENTS IN AUSTRALIA AND CHINA. B.COLUMN OF HOPE AND THE PRIMARY INVESTIGATOR WILL WORK TO EXPAND THE DATA SET TO INCLUDE PATIENTS OF MORE THOUGHT LEADERS IN THE FIELD. B)DETERMINING THE NEXT STEPS IN RESOLVING SYRINGOMYELIA, USING THE POST TRAUMATIC SYRINGOMYELIA MODELS AND THE CHARI SURGERY STUDY RESULTS.
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc0FORM 990-EZ, PART I
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc1FORM 990-EZ, PART I, LINE 16
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc2FORM 990-EZ, PART III
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc3FORM 990-EZ, PART III, LINE 28
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc4FORM 990-EZ, PART III, LINE 29
ReturnHeader/BuildTS02025-03-06 01:10:19Z
ReturnHeader/BusinessOfficerGrp/DiscussWithPaidPreparerInd0true
ReturnHeader/BusinessOfficerGrp/PersonNm0MARK S KANE
ReturnHeader/BusinessOfficerGrp/PersonTitleTxt0PRESIDENT
ReturnHeader/BusinessOfficerGrp/PhoneNum07166337022
ReturnHeader/BusinessOfficerGrp/SignatureDt02025-05-11
ReturnHeader/Filer/BusinessName/BusinessNameLine1Txt0CHIARI & SYRINGOMYELIA RESEARCH
ReturnHeader/Filer/BusinessName/BusinessNameLine2Txt0FOUNDATION INC
ReturnHeader/Filer/BusinessNameControlTxt0CHIA
ReturnHeader/Filer/EIN0201959386
ReturnHeader/Filer/PhoneNum07166337022
ReturnHeader/Filer/USAddress/AddressLine1Txt0228 GARRY DRIVE
ReturnHeader/Filer/USAddress/CityNm0WEST SENECA
ReturnHeader/Filer/USAddress/StateAbbreviationCd0NY
ReturnHeader/Filer/USAddress/ZIPCd014224
ReturnHeader/IRSResponsiblePrtyInfoCurrInd0false
ReturnHeader/PreparerFirmGrp/PreparerFirmEIN0272004914
ReturnHeader/PreparerFirmGrp/PreparerFirmName/BusinessNameLine1Txt0EDWARD L ARCARA CPA PC
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/AddressLine1Txt0465 FRANKLIN ST
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/CityNm0BUFFALO
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/StateAbbreviationCd0NY
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/ZIPCd0142021301
ReturnHeader/PreparerPersonGrp/PhoneNum07168842492
ReturnHeader/PreparerPersonGrp/PreparationDt02025-05-12
ReturnHeader/PreparerPersonGrp/PreparerPersonNm0EDWARD L ARCARA CPA
ReturnHeader/ReturnTs02025-05-12T16:24:40-04:00
ReturnHeader/ReturnTypeCd0990EZ
ReturnHeader/TaxPeriodBeginDt02024-01-01
ReturnHeader/TaxPeriodEndDt02024-12-31
ReturnHeader/TaxYr02024

Document Assets

No mirrored PDF or thumbnail assets are attached yet.